Publication Name	World Journal of Stem Cells
Manuscript ID	13889
Country	France

Received	2014-09-05 19:00
Peer-Review Started	2014-09-06 11:51
To Make the First Decision	2014-12-17 11:19
Return for Revision	2014-12-20 21:02
Revised	2014-12-28 00:22
Second Decision	2015-06-09 13:29
Accepted by Journal Editor-in-Chief	2015-06-11 10:06
Accepted by Company Editor-in-Chief	2015-06-19 16:57
Articles in Press	2015-06-19 16:57
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-08-15 21:49
Publish the Manuscript Online	2015-08-27 10:51

ISSN	1948-0210 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Review
Article Title	Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors
Manuscript Source	Invited Manuscript
All Author List	Maël Heiblig, Mohamed Elhamri, Mauricette Michallet and Xavier Thomas
Funding Agency and Grant Number
Corresponding Author	Xavier Thomas, MD, PhD, Hematology Department, Lyon-Sud Hospital, 165 chemin du Grand Revoyet, 69495 Pierre Bénite cedex, France. xavier.thomas@chu-lyon.fr
Key Words	Chimeric antigen receptors; Adoptive immu­no­therapy; Acute leukemia; T cells; Immune surveil­lance
Core Tip	Leukemia cells ultimately escape to the immune system, due to various mechanisms such as limited availability of tumor specific T cells or down-regulation in major histocompatibility complex expression. Chimeric antigen receptor (CAR) T cell technology redirects immune reactivity towards a broad variety of chosen antigens in a human leukocyte antigen-independent manner. Recent introduction of co-stimulatory domains in the CAR construct enhances significantly in vitro and in vivo expansion and persistence of these genetically modified T cells. First clinical trials, especially with anti-CD19 CAR T cells, report promising results in acute lymphoblastic leukemia.
Publish Date	2015-08-27 10:51
Citation	Heiblig M, Elhamri M, Mauricette M, Thomas X. Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. World J Stem Cells 2015; 7(7): 1022-1038
URL	http://www.wjgnet.com/1948-0210/full/v7/i7/1022.htm
DOI	http://dx.doi.org/10.4252/wjsc.v7.i7.1022

Full Article (PDF)	WJSC-7-1022.pdf
Full Article (Word)	WJSC-7-1022.doc
Manuscript File	13889-Review.doc
Answering Reviewers	13889-Answering reviewers.pdf
Audio Core Tip	13889-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	13889-Conflict-of-interest statement.pdf
Copyright License Agreement	13889-Copyright assignment.pdf
Peer-review Report	13889-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	13889-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	13889-Scientific misconduct check.pdf
Scientific Editor Work List	13889-Scientific editor work list.pdf